GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » Piotroski F-Score

Genocea Biosciences (Genocea Biosciences) Piotroski F-Score

: 0 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genocea Biosciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Genocea Biosciences's Piotroski F-Score or its related term are showing as below:


Genocea Biosciences Piotroski F-Score Historical Data

The historical data trend for Genocea Biosciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 1.00 3.00 4.00 1.00

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 2.00 2.00 1.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar22) TTM:Last Year (Mar21) TTM:
Net Income was -4.311 + -3.622 + -13.28 + -15.978 = $-37.19 Mil.
Cash Flow from Operations was -10.512 + -11.36 + -11.105 + -15.209 = $-48.19 Mil.
Revenue was 0 + 1.641 + 0 + 0.27 = $1.91 Mil.
Gross Profit was 0 + 1.641 + 0 + 0.27 = $1.91 Mil.
Average Total Assets from the begining of this year (Mar21)
to the end of this year (Mar22) was
(83.938 + 77.383 + 64.918 + 55.967 + 38.788) / 5 = $64.1988 Mil.
Total Assets at the begining of this year (Mar21) was $83.94 Mil.
Long-Term Debt & Capital Lease Obligation was $8.37 Mil.
Total Current Assets was $24.41 Mil.
Total Current Liabilities was $18.03 Mil.
Net Income was -11.321 + -4.555 + -14.985 + -11.983 = $-42.84 Mil.

Revenue was 0.906 + 0.453 + 0 + 0 = $1.36 Mil.
Gross Profit was 0.906 + 0.453 + 0 + 0 = $1.36 Mil.
Average Total Assets from the begining of last year (Mar20)
to the end of last year (Mar21) was
(45.192 + 40.516 + 106.198 + 98.493 + 83.938) / 5 = $74.8674 Mil.
Total Assets at the begining of last year (Mar20) was $45.19 Mil.
Long-Term Debt & Capital Lease Obligation was $15.49 Mil.
Total Current Assets was $68.82 Mil.
Total Current Liabilities was $11.42 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genocea Biosciences's current Net Income (TTM) was -37.19. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genocea Biosciences's current Cash Flow from Operations (TTM) was -48.19. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar21)
=-37.191/83.938
=-0.44307703

ROA (Last Year)=Net Income/Total Assets (Mar20)
=-42.844/45.192
=-0.9480439

Genocea Biosciences's return on assets of this year was -0.44307703. Genocea Biosciences's return on assets of last year was -0.9480439. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Genocea Biosciences's current Net Income (TTM) was -37.19. Genocea Biosciences's current Cash Flow from Operations (TTM) was -48.19. ==> -48.19 <= -37.19 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=8.373/64.1988
=0.130423

Gearing (Last Year: Mar21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar20 to Mar21
=15.488/74.8674
=0.20687242

Genocea Biosciences's gearing of this year was 0.130423. Genocea Biosciences's gearing of last year was 0.20687242. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar22)=Total Current Assets/Total Current Liabilities
=24.408/18.03
=1.35374376

Current Ratio (Last Year: Mar21)=Total Current Assets/Total Current Liabilities
=68.82/11.424
=6.02415966

Genocea Biosciences's current ratio of this year was 1.35374376. Genocea Biosciences's current ratio of last year was 6.02415966. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Genocea Biosciences's number of shares in issue this year was 71.12. Genocea Biosciences's number of shares in issue last year was 74.22. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.911/1.911
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.359/1.359
=1

Genocea Biosciences's gross margin of this year was 1. Genocea Biosciences's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar21)
=1.911/83.938
=0.0227668

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar20)
=1.359/45.192
=0.03007169

Genocea Biosciences's asset turnover of this year was 0.0227668. Genocea Biosciences's asset turnover of last year was 0.03007169. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genocea Biosciences has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Genocea Biosciences  (OTCPK:GNCAQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Genocea Biosciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Genocea Biosciences (Genocea Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Executives
Jacquelyn L Sumer officer: CHIEF LEGAL & COMPLIANCE OFF C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber director 2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall officer: CHIEF FINANCIAL OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell 10 percent owner
Stapleton Raymond D Jr officer: EVP PHARM SCI & MFG C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner officer: VP of Research C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815

Genocea Biosciences (Genocea Biosciences) Headlines